ResearcherMayo ClinicNo recent work listed

Benjamin Edward Ueberroth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8882-2348; OpenAlex author ID A5055968903. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.06.009 ↗
Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s12029-020-00378-z ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tanios Bekaii‐Saab · 1 shared paper, 2022 · strength 0.26
- Paper Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognos… DOI 10.1016/j.pan.2022.06.009 ↗
Kevin Juan Zhang · 1 shared paper, 2021 · strength 0.19
- Paper Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic A… DOI 10.1007/s12029-020-00378-z ↗
Philip A. Philip · 1 shared paper, 2021 · strength 0.19
- Paper Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic A… DOI 10.1007/s12029-020-00378-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.